AN EARLY ASSESSMENT OF THE EFFICACY OF MEDICINES IN THE TREATMENT OF PATIENTS WITH COVID - 19

AN EARLY ASSESSMENT OF THE EFFICACY OF MEDICINES IN THE TREATMENT OF PATIENTS WITH COVID - 19

A. S. Kolbin

Coronavirus disease-2019 is considered the very recent challenge to world community. While still lacking specific vaccines, the healthcare system is in urgent need for effective and safe medical drugs. We have evaluated the medical technologies for COVID-19 which are under study now. The search was conducted on СlinicalTrials.gov until the start of April 2020. Hence, it was shown that the worldwide rise in new clinical trials concerning COVID-19 is increasing by 65% per week. The interventional Phase II and III clinical trials are more often performed. Most studies are scheduled or conducted in Western Europe (n = 92), China (n = 79), and the United States (n = 51). Surrogate outcome points are usually evaluated, such as clinical recovery, recovery based on clinical scores of symptoms (fever, cough, diarrhea, myalgia, shortness of breath), lack of dyspnea progression, rate of artificial ventilation, rates of admission to the ICU, etc. Antimalarial drugs that are mostly studied. At the present time, it is not possible to discuss efficacy and safety of any drug in the COVID-19 treatment, since most studies are launched quiet recently. The therapeutic regimens proposed now in clinical recommendations are not evidence-based, and appropriate studies are, at best, still considered hypothetic.

2019

chloroquine, Clinical trials, Monoclonal Antibodies, hydroxychloroquine, Lopinavir/ritonavir, Coronavirus infection, remdesivir, COVID-19

DOI: 10.15789/2220-7619-AEA-1458

Infekciâ i Immunitet

Sankt-Peterburg : NIIÈM imeni Pastera

Infectious and parasitic diseases